tiprankstipranks
Trending News
More News >
Penumbra (PEN)
NYSE:PEN
US Market
Advertisement

Penumbra (PEN) Stock Forecast & Price Target

Compare
450 Followers
See the Price Targets and Ratings of:

PEN Analyst Ratings

Strong Buy
17Ratings
Strong Buy
13 Buy
4 Hold
0 Sell
Based on 17 analysts giving stock ratings to
Penumbra
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

PEN Stock 12 Month Forecast

Average Price Target

$307.20
▲(12.64% Upside)
Based on 17 Wall Street analysts offering 12 month price targets for Penumbra in the last 3 months. The average price target is $307.20 with a high forecast of $350.00 and a low forecast of $265.00. The average price target represents a 12.64% change from the last price of $272.73.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"190":"$190","351":"$351","230.25":"$230.3","270.5":"$270.5","310.75":"$310.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":350,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$350.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":307.2,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$307.20</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":265,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$265.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[190,230.25,270.5,310.75,351],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Mar<br/>2025","9":"Jun<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,269.5,275.6923076923077,281.88461538461536,288.0769230769231,294.2692307692308,300.46153846153845,306.65384615384613,312.84615384615387,319.03846153846155,325.2307692307692,331.4230769230769,337.61538461538464,343.8076923076923,{"y":350,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,269.5,272.4,275.3,278.2,281.1,284,286.9,289.8,292.7,295.59999999999997,298.5,301.4,304.3,{"y":307.2,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,269.5,269.15384615384613,268.8076923076923,268.46153846153845,268.11538461538464,267.7692307692308,267.4230769230769,267.0769230769231,266.7307692307692,266.38461538461536,266.03846153846155,265.6923076923077,265.34615384615387,{"y":265,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":202.32,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":191.56,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":233.3,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":244.84,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":237.48,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":266.97,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":285.44,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":271.13,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":291.82,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":256.16,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":250.68,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":243.01,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":269.5,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$350.00Average Price Target$307.20Lowest Price Target$265.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Bank of America Securities Analyst forecast on PEN
Bank of America Securities
Bank of America Securities
$320
Buy
17.33%
Upside
Reiterated
09/10/25
Positive Outlook on Penumbra's Stock Driven by Ruby XL's Market Impact and Efficiency Gains
Needham
Hold
Reiterated
09/08/25
Penumbra (PEN) Receives a Hold from Needham
Evercore ISI Analyst forecast on PEN
Evercore ISI
Evercore ISI
$300
Buy
10.00%
Upside
Initiated
09/02/25
Penumbra initiated with an Outperform at Evercore ISIPenumbra initiated with an Outperform at Evercore ISI
TR | OpenAI - 4o Analyst forecast on PEN
TR | OpenAI - 4o
TR | OpenAI - 4o
$295$302
Buy
10.73%
Upside
Reiterated
08/27/25
AI Generated ArticleAI Generated Article
Canaccord Genuity Analyst forecast on PEN
Canaccord Genuity
Canaccord Genuity
$350
Buy
28.33%
Upside
Reiterated
08/12/25
Penumbra's Strategic Growth Initiatives and Market Expansion Drive Buy Rating
RBC Capital
$325
Buy
19.17%
Upside
Reiterated
08/11/25
RBC Capital Sticks to Its Buy Rating for Penumbra (PEN)
Morgan Stanley Analyst forecast on PEN
Morgan Stanley
Morgan Stanley
$260$266
Hold
-2.47%
Downside
Reiterated
07/31/25
Morgan Stanley Remains a Hold on Penumbra (PEN)
UBS
$330$335
Buy
22.83%
Upside
Reiterated
07/31/25
Penumbra price target raised to $335 from $330 at UBSPenumbra price target raised to $335 from $330 at UBS
Truist Financial Analyst forecast on PEN
Truist Financial
Truist Financial
$300$310
Buy
13.67%
Upside
Reiterated
07/30/25
Truist Financial Reaffirms Their Buy Rating on Penumbra (PEN)
Wells Fargo Analyst forecast on PEN
Wells Fargo
Wells Fargo
$315$290
Buy
6.33%
Upside
Reiterated
07/30/25
Analysts Conflicted on These Healthcare Names: Merck & Company (NYSE: MRK), Incyte (NASDAQ: INCY) and Penumbra (NYSE: PEN)
J.P. Morgan Analyst forecast on PEN
J.P. Morgan
J.P. Morgan
$285$265
Hold
-2.83%
Downside
Reiterated
07/30/25
Penumbra (PEN) Gets a Hold from J.P. Morgan
Nephron
$305
Buy
11.83%
Upside
Upgraded
07/30/25
Positive Report for Penumbra (PEN) from Nephron
Leerink Partners Analyst forecast on PEN
Leerink Partners
Leerink Partners
$327
Buy
19.90%
Upside
Reiterated
07/30/25
Penumbra's Strong Growth Potential and Strategic Developments Reinforce Buy RatingWe are reiterating our Outperform rating on PEN and maintaining our $327 PT following the company's 2Q results. PEN reported WW sales +4% vs. consensus, with WW Thrombectomy +1% vs. consensus and WW E&A sales +11% vs. consensus. We were particularly encouraged by another consecutive quarter of strong growth in VTE, with PEN's US VTE business growing +42% y/y. MSD growth of PEN's US Stroke business came in a bit soft, with the company citing flat market growth, though our sense is that expectations were low coming into the print. Notably, PEN announced an expansion of its sales force, including the addition of new E&A reps while existing reps focus more exclusively on PEN's thrombectomy business.
Robert W. Baird Analyst forecast on PEN
Robert W. Baird
Robert W. Baird
$283$285
Buy
4.50%
Upside
Reiterated
07/30/25
Penumbra price target raised to $285 from $283 at BairdPenumbra price target raised to $285 from $283 at Baird
William Blair Analyst forecast on PEN
William Blair
William Blair
Buy
Reiterated
07/30/25
Penumbra's Promising Outlook: Buy Rating Amid Strong Performance and Strategic Growth OpportunitiesWednesday, July 30, 2025 12:59 AM William Blair Equity Research | Healthcare Penumbra, Inc.
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Bank of America Securities Analyst forecast on PEN
Bank of America Securities
Bank of America Securities
$320
Buy
17.33%
Upside
Reiterated
09/10/25
Positive Outlook on Penumbra's Stock Driven by Ruby XL's Market Impact and Efficiency Gains
Needham
Hold
Reiterated
09/08/25
Penumbra (PEN) Receives a Hold from Needham
Evercore ISI Analyst forecast on PEN
Evercore ISI
Evercore ISI
$300
Buy
10.00%
Upside
Initiated
09/02/25
Penumbra initiated with an Outperform at Evercore ISIPenumbra initiated with an Outperform at Evercore ISI
TR | OpenAI - 4o Analyst forecast on PEN
TR | OpenAI - 4o
TR | OpenAI - 4o
$295$302
Buy
10.73%
Upside
Reiterated
08/27/25
AI Generated ArticleAI Generated Article
Canaccord Genuity Analyst forecast on PEN
Canaccord Genuity
Canaccord Genuity
$350
Buy
28.33%
Upside
Reiterated
08/12/25
Penumbra's Strategic Growth Initiatives and Market Expansion Drive Buy Rating
RBC Capital
$325
Buy
19.17%
Upside
Reiterated
08/11/25
RBC Capital Sticks to Its Buy Rating for Penumbra (PEN)
Morgan Stanley Analyst forecast on PEN
Morgan Stanley
Morgan Stanley
$260$266
Hold
-2.47%
Downside
Reiterated
07/31/25
Morgan Stanley Remains a Hold on Penumbra (PEN)
UBS
$330$335
Buy
22.83%
Upside
Reiterated
07/31/25
Penumbra price target raised to $335 from $330 at UBSPenumbra price target raised to $335 from $330 at UBS
Truist Financial Analyst forecast on PEN
Truist Financial
Truist Financial
$300$310
Buy
13.67%
Upside
Reiterated
07/30/25
Truist Financial Reaffirms Their Buy Rating on Penumbra (PEN)
Wells Fargo Analyst forecast on PEN
Wells Fargo
Wells Fargo
$315$290
Buy
6.33%
Upside
Reiterated
07/30/25
Analysts Conflicted on These Healthcare Names: Merck & Company (NYSE: MRK), Incyte (NASDAQ: INCY) and Penumbra (NYSE: PEN)
J.P. Morgan Analyst forecast on PEN
J.P. Morgan
J.P. Morgan
$285$265
Hold
-2.83%
Downside
Reiterated
07/30/25
Penumbra (PEN) Gets a Hold from J.P. Morgan
Nephron
$305
Buy
11.83%
Upside
Upgraded
07/30/25
Positive Report for Penumbra (PEN) from Nephron
Leerink Partners Analyst forecast on PEN
Leerink Partners
Leerink Partners
$327
Buy
19.90%
Upside
Reiterated
07/30/25
Penumbra's Strong Growth Potential and Strategic Developments Reinforce Buy RatingWe are reiterating our Outperform rating on PEN and maintaining our $327 PT following the company's 2Q results. PEN reported WW sales +4% vs. consensus, with WW Thrombectomy +1% vs. consensus and WW E&A sales +11% vs. consensus. We were particularly encouraged by another consecutive quarter of strong growth in VTE, with PEN's US VTE business growing +42% y/y. MSD growth of PEN's US Stroke business came in a bit soft, with the company citing flat market growth, though our sense is that expectations were low coming into the print. Notably, PEN announced an expansion of its sales force, including the addition of new E&A reps while existing reps focus more exclusively on PEN's thrombectomy business.
Robert W. Baird Analyst forecast on PEN
Robert W. Baird
Robert W. Baird
$283$285
Buy
4.50%
Upside
Reiterated
07/30/25
Penumbra price target raised to $285 from $283 at BairdPenumbra price target raised to $285 from $283 at Baird
William Blair Analyst forecast on PEN
William Blair
William Blair
Buy
Reiterated
07/30/25
Penumbra's Promising Outlook: Buy Rating Amid Strong Performance and Strategic Growth OpportunitiesWednesday, July 30, 2025 12:59 AM William Blair Equity Research | Healthcare Penumbra, Inc.
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Penumbra

1 Month
xxx
Success Rate
16/22 ratings generated profit
73%
Average Return
+7.25%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 72.73% of your transactions generating a profit, with an average return of +7.25% per trade.
3 Months
xxx
Success Rate
11/18 ratings generated profit
61%
Average Return
+7.21%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 61.11% of your transactions generating a profit, with an average return of +7.21% per trade.
1 Year
Success Rate
17/22 ratings generated profit
77%
Average Return
+20.65%
reiterated a buy rating last month
Copying Shagun Singh Chadha's trades and holding each position for 1 Year would result in 77.27% of your transactions generating a profit, with an average return of +20.65% per trade.
2 Years
xxx
Success Rate
19/22 ratings generated profit
86%
Average Return
+22.77%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 86.36% of your transactions generating a profit, with an average return of +22.77% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

PEN Analyst Recommendation Trends

Rating
May 25
Jun 25
Jul 25
Aug 25
Sep 25
Strong Buy
0
0
0
0
0
Buy
22
23
22
25
25
Hold
6
5
9
7
8
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
28
28
31
32
33
In the current month, PEN has received 25 Buy Ratings, 8 Hold Ratings, and 0 Sell Ratings. PEN average Analyst price target in the past 3 months is 307.20.
Each month's total comprises the sum of three months' worth of ratings.

PEN Financial Forecast

PEN Earnings Forecast

Next quarter’s earnings estimate for PEN is $0.93 with a range of $0.85 to $1.03. The previous quarter’s EPS was $0.86. PEN beat its EPS estimate 100.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 50.00% of the time in the same period. In the last calendar year PEN has Outperformed its overall industry.
Next quarter’s earnings estimate for PEN is $0.93 with a range of $0.85 to $1.03. The previous quarter’s EPS was $0.86. PEN beat its EPS estimate 100.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 50.00% of the time in the same period. In the last calendar year PEN has Outperformed its overall industry.

PEN Sales Forecast

Next quarter’s sales forecast for PEN is $340.94M with a range of $336.19M to $345.00M. The previous quarter’s sales results were $339.45M. PEN beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 55.07% of the time in the same period. In the last calendar year PEN has Outperformed its overall industry.
Next quarter’s sales forecast for PEN is $340.94M with a range of $336.19M to $345.00M. The previous quarter’s sales results were $339.45M. PEN beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 55.07% of the time in the same period. In the last calendar year PEN has Outperformed its overall industry.

PEN Stock Forecast FAQ

What is PEN’s average 12-month price target, according to analysts?
Based on analyst ratings, Penumbra’s 12-month average price target is 307.20.
    What is PEN’s upside potential, based on the analysts’ average price target?
    Penumbra has 12.64% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is PEN a Buy, Sell or Hold?
          Penumbra has a consensus rating of Strong Buy which is based on 13 buy ratings, 4 hold ratings and 0 sell ratings.
            What is Penumbra’s price target?
            The average price target for Penumbra is 307.20. This is based on 17 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $350.00 ,the lowest forecast is $265.00. The average price target represents 12.64% Increase from the current price of $272.73.
              What do analysts say about Penumbra?
              Penumbra’s analyst rating consensus is a Strong Buy. This is based on the ratings of 17 Wall Streets Analysts.
                How can I buy shares of PEN?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis